Summary of the Conference Call Company Overview - The company discussed is Aptar, which operates primarily in the pharmaceutical, beauty, personal care, home care, food, and beverage sectors [2][3][5] - Approximately 46% of Aptar's business is in the pharmaceutical sector, which is the most profitable and rapidly growing segment [3][11] Key Business Segments Pharmaceutical Business - The pharmaceutical segment includes proprietary dispensing devices such as nasal sprays and injectables, notably GLP-1 [3][11] - The company has increased its core sales growth rate for the pharmaceutical business to 7-11% from a previous range of 6-10% [11] - The pharmaceutical business has a compound annual growth rate (CAGR) of about 8% over the last decade [11] - The segment contributes nearly 70% of the company's EBITDA [17] Beauty and Personal Care - The beauty segment has faced challenges but is expected to improve due to cost improvements and productivity enhancements [12][34] - China is a significant market for beauty products, with the average consumer basket containing twice as many beauty products compared to the West [34][55] - The company has undergone a significant renovation process in its beauty business, including upgrading assets and reducing non-competitive plants [34] Closures Business - The closures segment is known for innovative products like the upside-down ketchup bottle, which has expanded into various condiments and personal care products [36][38] - This segment is primarily US-focused and has been able to drive growth through converting markets to use Aptar's products [41] Financial Performance and Targets - The adjusted EBITDA target for the total company has been increased to 21-23% [11] - The return on invested capital target has been raised to 11-13% [11] - The company has returned nearly $800 million to shareholders through dividends and share buybacks from 2019 to 2024 [13] - The company maintains a strong balance sheet with a leverage ratio of 1.16, allowing for continued investment in growth opportunities [14] Sustainability and Competitive Advantage - Sustainability is a core part of Aptar's business model, providing a competitive advantage [7][15] - The company has received recognition for its sustainability efforts, including being in the top 1% of companies ranked by EcoVadis [15][16] Market Trends and Growth Drivers - There is a trend of repurposing existing drugs for nasal delivery, which is driving growth in the pharmaceutical segment [22][24] - The rise in allergic rhinitis cases, particularly in Asia, is another growth driver for the pharmaceutical business [24][25] - The company benefits from its intellectual property, allowing it to maintain revenue even when products go generic or over-the-counter [25][26] Customer Dynamics and Market Conditions - Customer conversations indicate a cautious approach to strategic actions due to ongoing tariff uncertainties [45][46] - The company has observed a resurgence in consumer confidence in China, which is expected to positively impact the beauty segment [54][55] Conclusion - Aptar is positioned for long-term growth with a focus on innovation, sustainability, and a strong balance sheet, despite facing challenges in certain segments [11][12][14]

Market Overview - A recent ruling by the U.S. trade court declared President Trump's global tariffs illegal, contributing to a new wave of market uncertainty [1] - The Federal Reserve's current wait-and-see approach adds to the uncertainty regarding future interest rate directions [1] Investment Strategy - Creating a curated portfolio of low-beta stocks is recommended as a strategy to navigate market volatility [1] - Low-beta stocks are less volatile than the market, providing a safeguard against uncertainty [1] Stock Recommendations - Suggested stocks include Natural Gas Services Group Inc (NGS), Stride Inc. (LRN), AptarGroup Inc. (ATR), and Philip Morris International Inc. (PM) [2] Stock Characteristics - Beta measures the volatility of a stock relative to the market, with a beta of 1 indicating movement in line with the market [3][4] - Stocks with a beta between 0 and 0.6 are screened for lower volatility [5] Screening Criteria - Stocks must have a positive price change over the last four weeks [5] - Average 20-day trading volume should exceed 50,000 to ensure liquidity [6] - Stocks must be priced at $5 or higher [6] - Zacks Rank of 1 indicates strong buy potential, suggesting significant outperformance over the next one to three months [6] Company Insights - **Natural Gas Services (NGS)**: Increased demand for liquefied natural gas (LNG) exports is driving the need for compression equipment, benefiting NGS as more pipelines are built [7] - **AptarGroup (ATR)**: Positioned for growth due to trends in healthcare moving towards home settings and rising demand for drug delivery systems [8] - **Stride Inc. (LRN)**: Focuses on innovative educational solutions, benefiting from the growing demand for school choice and tutoring services [10] - **Philip Morris International (PM)**: Transitioning from traditional cigarettes to smoke-free products, with a focus on shareholder rewards and cost-cutting initiatives [11]

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profitability and price performance [1] - It highlights specific efficiency ratios that can be used to evaluate companies, including Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin [2][3][4][5] Efficiency Ratios - **Receivables Turnover**: This ratio measures a company's ability to extend credit and collect debts, with a higher ratio indicating better performance [2] - **Asset Utilization**: This ratio assesses how effectively a company converts its assets into sales, with higher values suggesting greater efficiency [3] - **Inventory Turnover**: This ratio indicates how well a company manages its inventory relative to its cost of goods sold, with higher values reflecting better inventory management [4] - **Operating Margin**: This ratio evaluates a company's ability to control operating expenses, with higher values indicating more efficient expense management [5] Screening Criteria - The article mentions that companies were screened based on the aforementioned efficiency ratios being greater than industry averages, narrowing down the selection to eight stocks [7] - A favorable Zacks Rank of 1 (Strong Buy) was also included in the screening criteria to enhance profitability [6] Selected Companies - **Microvast (MVST)**: A technology company specializing in lithium-ion battery solutions, with an average four-quarter earnings surprise of 88.8% [8] - **Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS)**: Provides public water and sewage services in Sao Paulo, with an average four-quarter earnings surprise of 30.8% [8] - **CarGurus (CARG)**: An online automotive marketplace with an average four-quarter earnings surprise of nearly 11.8% [9] - **AptarGroup (ATR)**: A global supplier of innovative packaging solutions, with an average four-quarter earnings surprise of nearly 7.3% [9]

Core Viewpoint - AptarGroup, Inc. (ATR) is positioned for growth through its business transformation plan, innovative product launches, and strategic acquisitions [1] Group 1: Business Transformation - The company is focused on business transformation to drive top-line growth, enhance operational excellence, and improve organizational effectiveness [2] - The Beauty segment is undergoing transformation with new capabilities in Asia, cost reduction, and strategies to capitalize on fast-growing application fields [3] Group 2: Segmental Demand - The Pharma segment is experiencing strong demand for proprietary dispensing devices used in various medical applications, with a long-term sales growth target of 7-11% [4] - The Beauty segment is seeing increased sales in prestige and mass fragrances, as well as skin care and color cosmetic solutions, supported by a positive mix of pricing and volume growth [5] Group 3: Strategic Acquisitions - AptarGroup is committed to expanding through acquisitions to enhance technology, geographic presence, and product offerings [5] - In February 2024, Aptar Digital Health acquired Healint to strengthen its digital health portfolio in neurology and signed an agreement with Biogen for digital health solutions [6] - In October 2024, AptarGroup acquired SipNose Nasal Delivery Systems' device technology assets to enhance its intranasal delivery product development [7] Group 4: Innovative Product Launches - The Pharma segment had the highest number of product launches since 2018, with continued momentum expected in 2024 and 2025 [7] - Notable product applications include a nasal delivery system for saline rinse in Germany and an ophthalmic squeeze dispenser in China [8] - In the Beauty segment, various custom dispensing solutions are being utilized by major brands such as L'Oreal and P&G [9] Group 5: Market Performance - ATR shares have increased by 7.8% over the past year, contrasting with a 6.3% decline in the industry [12]

AptarGroup (ATR) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this maker of consumer-product dispensing systems is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate re ...

Core Viewpoint - AptarGroup (ATR) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for AptarGroup projects earnings of $5.87 per share for the fiscal year ending December 2025, reflecting a year-over-year increase of 4.1% [9]. - Over the past three months, the Zacks Consensus Estimate for AptarGroup has risen by 3.6%, indicating a trend of increasing earnings estimates [9]. Zacks Rating System - The Zacks rating system is based solely on changes in a company's earnings picture, making it a reliable tool for investors to gauge stock performance [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of AptarGroup to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting a strong potential for price appreciation in the near term [11].

Core Insights - AptarGroup, Inc. reported improved margins in Q1 2025, with adjusted earnings per share of $1.20, surpassing the Zacks Consensus Estimate of $1.16, although it represented a 1.6% decrease from $1.22 in the same quarter last year [1][2] Financial Performance - Total revenues for Q1 2025 decreased by 3.1% year over year to $887 million, missing the Zacks Consensus Estimate of $900 million, with core sales remaining flat [3] - Cost of sales fell by 5.5% year over year to $551 million, while gross profit increased by 1.1% to $336 million, resulting in a gross margin of 37.9%, up from 36.3% in the prior year [3] - Selling, research, development, and administrative expenses rose by 1.6% year over year to $155 million, with adjusted operating income increasing by 2.8% to $118 million, leading to an adjusted operating margin of 13.3%, up from 12.5% [4] Segment Performance - The Pharma segment saw a revenue increase of 0.5% year over year to $409.5 million, exceeding the estimate of $403 million, with adjusted operating income rising by 7.7% to $111 million [5] - The Beauty segment experienced a revenue decline of 6.6% year over year to $306 million, falling short of the estimated $313 million, while operating income decreased by 14.2% to $17 million [6] - The Closures segment's revenues decreased by 4.8% year over year to $172 million, also missing the estimate of $179 million, but operating income slightly increased to $13.7 million [7] Cash Position - As of March 31, 2025, AptarGroup reported cash and cash equivalents of $126 million, down from $224 million at the end of 2024, with cash flow from operations at $83 million compared to $92 million in the previous year [8] Future Outlook - The company estimates adjusted earnings per share for Q2 2024 to be between $1.56 and $1.64 [9] Stock Performance - ATR shares have increased by 2.7% over the past year, contrasting with a 12% decline in the industry [10]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Gr ...

Financial Performance - Reported net sales for Q1 2025 decreased by 3% to $887.3 million compared to $915.4 million in Q1 2024, with core sales remaining flat [155]. - Operating income rose by approximately $1.4 million to $113.4 million in Q1 2025, with an operating income margin of 12.8%, up from 12.2% in the prior year [167]. - Adjusted EBITDA for Q1 2025 increased by 8% to $142.5 million, with an adjusted EBITDA margin of 34.8%, compared to 32.5% in Q1 2024 [180]. - Reported net income for Q1 2025 was $78.7 million, with reported income before income taxes at $106.0 million [205]. - Reported net income for the first quarter of 2025 was $82.9 million, resulting in a reported net income margin of 9.1% [206]. - Adjusted EBITDA for the first quarter of 2025 was $178.8 million, with an adjusted EBITDA margin of 19.5% [206]. - Free cash flow increased to $25.9 million in Q1 2025 from $16.7 million in Q1 2024, indicating improved cash generation [209]. Segment Performance - The Pharma segment reported net sales of $409.5 million, a 1% increase, with core sales growth of 3% driven by strong demand in prescription drugs [178]. - The Beauty segment experienced a 7% decline in net sales to $305.7 million, with core sales down 3% due to lower European demand [184]. - Net sales for Q1 2025 decreased approximately 5% to $172.1 million compared to $180.8 million in Q1 2024, with core sales down approximately 2% [191]. - Core sales to food and beverage markets each increased by 6%, but overall core sales remained flat due to lower tooling sales compared to Q1 2024 [191]. - Personal care sales declined by 18%, while other markets improved by 7% driven by strong laundry and dish care product sales [192]. - The overall reported net sales growth for the food market was down 2%, while the beverage market reported a 3% decline [192]. Expenses and Costs - SG&A expenses increased to $155.3 million in Q1 2025, representing 17.5% of net sales, up from 16.7% in Q1 2024 [161]. - Interest expense rose to $11.4 million in Q1 2025, reflecting refinancing activities and new term loan arrangements [169]. - Restructuring costs for Q1 2025 were $2.0 million, down from $3.5 million in Q1 2024, with a cumulative expense of $66.7 million as of March 31, 2025 [165]. - Corporate & Other costs increased to $23.5 million in Q1 2025 from $21.6 million in Q1 2024, primarily due to higher incentive compensation costs [197]. Tax and Financial Ratios - The effective tax rate increased to 25.8% in Q1 2025 from 20.5% in Q1 2024, primarily due to a temporary surtax in France and lower tax benefits from share-based compensation [173]. - The company has a consolidated leverage ratio of 1.16 to 1.00, well below the maximum requirement of 3.50 to 1.00 [226]. - Earnings per share for Q2 2025 is expected to be in the range of $1.56 to $1.64, based on an effective tax rate of 19% to 21% due to a one-time tax benefit [237]. Cash and Debt Management - Net debt increased to $869.7 million as of March 31, 2025, compared to $800.2 million at December 31, 2024, resulting in a net debt to net capital ratio of 25.4% [218]. - Cash and equivalents decreased to $125.8 million at March 31, 2025, down from $223.8 million at December 31, 2024 [218]. - Total debt decreased slightly to $1.01 billion as of March 31, 2025, from $1.03 billion at December 31, 2024 [218]. - The company utilized $134.8 million in cash for financing activities in Q1 2025, primarily due to increased treasury stock purchases [221]. Dividends and Capital Expenditures - The company declared a quarterly cash dividend of $0.45 per share, payable on May 22, 2025 [228]. - Total estimated cash outlays for capital expenditures in 2025 are projected to be approximately $280 million to $300 million [237]. Risk Management and Strategic Focus - The company faces various risks including economic conditions, geopolitical conflicts, and supply chain disruptions that may impact future performance [239]. - The company has significant foreign exchange exposure primarily to the euro, with additional exposure to currencies such as the Chinese yuan and Brazilian real [242]. - The company is focused on optimizing fixed cost reduction initiatives and successfully implementing facility expansions [241]. - The company emphasizes the importance of managing worldwide customer launches of complex technical products, particularly in developing markets [241]. Currency and Hedging Activities - Currency rates negatively impacted net sales by 3%, highlighting the importance of constant currency analysis for performance evaluation [191]. - The company recorded the fair value of foreign currency forward exchange contracts of $0.6 million in prepaid and other and $0.2 million in accounts payable, accrued and other liabilities [244]. - A seven-year USD/EUR fixed-to-fixed cross currency interest rate swap was entered into to hedge interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032 [244]. - The fair value of the net investment hedge from the interest rate swap is reported as $17.0 million in accounts payable, accrued and other liabilities [244]. - The company anticipates that certain accounting standards issued by the FASB will not have a material impact on its financial statements upon adoption [235].

AptarGroup (ATR) Q1 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Mary Skafidas - Senior VP of IR & Corporate CommunicationsStephan Tanda - President, CEO & Executive DirectorVanessa Kanu - Executive VP & CFOGeorge Staphos - Managing Director Conference Call Participants Ghansham Panjabi - Senior Research AnalystMatthew Roberts - Equity Research AnalystDaniel Rizzo - AnalystMatt Larew - Research Analyst - HealthcareGabe Hajde - Analyst Operator Ladies and gentlemen, thank you for standing ...